📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
4
RECENT COVERAGE · 2 ARTICLES
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
CLDX received upgraded analyst support via UBS raising its price target to $45 from $38, maintaining a Buy conviction. This represents...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...
Celldex Therapeutics (CLDX) announced positive long-term efficacy data for barzolvolimab in treating chronic spontaneous urticaria (CSU)...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice